| scholarly article | Q13442814 |
| P50 | author | Shu Xing | Q42774641 |
| P2093 | author name string | Jian Luo | |
| Qi Zhang | |||
| Xueqi Fu | |||
| Qingshan Li | |||
| Zhizhuang Joe Zhao | |||
| Sanford B Krantz | |||
| Xuesong Xu | |||
| P2860 | cites work | The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes | Q35848032 |
| Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model | Q35849674 | ||
| Role of tyrosine kinases and phosphatases in polycythemia vera. | Q36279243 | ||
| Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders | Q38437889 | ||
| Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders | Q40347739 | ||
| JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia | Q42182981 | ||
| Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta | Q44104227 | ||
| Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders | Q46513376 | ||
| The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders | Q46735262 | ||
| The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia | Q27266125 | ||
| Oncogenic kinase signalling | Q28189493 | ||
| Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management | Q28191835 | ||
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2 | Q28243103 | ||
| Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia | Q28250886 | ||
| A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia | Q28253771 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
| JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. | Q33371084 | ||
| Identification of an acquired JAK2 mutation in polycythemia vera | Q33947635 | ||
| Polycythemia vera: myths, mechanisms, and management | Q34977300 | ||
| Jak family of kinases in cancer | Q35186465 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 339-342 | |
| P577 | publication date | 2006-08-31 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | JAK2(V617F): Prevalence in a large Chinese hospital population | |
| P478 | volume | 109 |
| Q37377284 | A progenitor cell origin of myeloid malignancies |
| Q42062133 | Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories |
| Q36306467 | Budd-Chiari Syndrome in a Patient with JAK-2 V617F and Factor V G1691A Mutations |
| Q36248587 | Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity |
| Q51781540 | Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods. |
| Q96230224 | Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking |
| Q37284926 | Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques |
| Q36374813 | Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders |
| Q33813824 | Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing |
| Q35521645 | Development of a highly sensitive method for detection of JAK2V617F |
| Q44345261 | Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population |
| Q24685474 | Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth |
| Q37250169 | Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090 |
| Q39363424 | Ethical considerations in genomic testing for hematologic disorders |
| Q39309957 | Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients |
| Q39276259 | Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population |
| Q28392728 | Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms |
| Q41902113 | High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms |
| Q54392855 | Impact of common thrombophilias and JAK2 V617F on pregnancy outcomes in unselected Italian women. |
| Q44985081 | JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome |
| Q33843882 | JAK2 V617F detected in two B-cell chronic lymphocytic leukemia patients without coexisting Philadelphia chromosome-negative myeloproliferative neoplasms: A report of two cases |
| Q47690928 | JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients |
| Q41499758 | JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association? |
| Q36036299 | JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate |
| Q54979638 | Jak-2 mutation frequency in patients with thrombocytosis. |
| Q53216529 | Janus Kinase V617F mutation in cigarette smokers. |
| Q61452103 | Janus kinase 2 V617F mutation in an unrelated peripheral blood stem cell donor |
| Q38816384 | Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group |
| Q54725630 | Mesenteric venous thrombosis secondary to an unsuspected JAK2 V617F-positive myeloproliferative disorder. |
| Q43979129 | Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations |
| Q38132817 | Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue |
| Q34375134 | Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. |
| Q39108026 | Occurrence of the JAK2 V617F mutation in patients with peripheral arterial disease |
| Q44265728 | Prevalence of JAK2V617F mutation in deep venous thrombosis patients and its clinical significance as a thrombophilic risk factor: Indian perspective |
| Q54545419 | Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study. |
| Q36261941 | Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients |
| Q34687245 | Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection |
| Q28239018 | Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits |
| Q34547493 | Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory |
| Q35643476 | Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg |
| Q91744844 | Response to the letter by Langabeer on "Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria" |
| Q30244631 | Review article: the aetiology of primary Budd-Chiari syndrome - differences between the West and China |
| Q92528596 | Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation |
| Q27317353 | Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion |
| Q42870221 | Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide |
| Q51741103 | Somatic and germline genetics at the JAK2 locus. |
| Q37783962 | Somatic mutations and the hierarchy of hematopoiesis |
| Q31017219 | Stochastic dynamics and the evolution of mutations in stem cells |
| Q38847693 | Targeting glutamine metabolism in myeloproliferative neoplasms |
| Q34612649 | The JAK2 V617F somatic mutation, mortality and cancer risk in the general population |
| Q81241494 | The JAK2(V617F) mutation may be present several years before the occurrence of overt myeloproliferative disorders |
| Q37209108 | The JAK2(V617F) tyrosine kinase mutation in blood donors with upper-limit haematocrit levels |
| Q45038631 | The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods |
| Q38830536 | The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study |
| Q36658043 | Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice |
| Q51354558 | Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms. |
Search more.